Спайдер повышается перед открытием торгов на NYSE.
- Европейские индексы на положительной территории.
SPY (внутридневной график) рост на премаркете премаркете. Поддержка 180.75 , сопротивления нет
Премаркет NYSE/NASDAQ:
Повышаются на премаркете:
- In reaction to strong earnings/guidance: ENTA +2.6%.
- M&A news: GA +10.5% (receives proposal from the co's Chairman to acquire the company at $11.75 per share).
- Select EU financial related names showing strength: NBG +1.7%, DB +1.5%, UBS +1.4%, LYG +1%, RBS +0.7%.
- Select 3-D printing names showing strength: VJET +5%, ONVO +4.9%, DDD +1.4%.
- Dialysis stocks gapping up on CMS payment rate changes for end-stage renaldisease facilities in 2014: FMS +7.3%, DVA +3.9%, NXTM +3.6%.
- Other news: OREX +19.7% (successful results of the interim analysis of the Light Study; co will resubmit the Contrave NDA in the next few weeks), ARIA +8.7% (cont strength), GLUU +6.9% (attributed to positive blog mention making the rounds), SIRI +4.9% (positive Barron's mention), JNY +4% (Sycamore in discussions to purchase JNY for $16/share, according to reports), CYCC +3.7% (announces data safety monitoring board recommendation to continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML), ANIK +3% (to join S&P SmallCap 600), STML +2.9% (presents results of clinical trial results with a synthetic peptide vaccine for brain cancer), DAL +2.1% (still checking), YGE +2% (to supply 15 MW PV modules to Solarcentury in the UK), BBY +1.9% (ticking higher on light volume by 2% following positive mention on MadMoney), RPRX +1.2% (reports it has been granted a face to face meeting with the FDA to discuss the pivotal Androxal efficacy studies), KTOS +1% (discontinues proposed refinancing effort), YHOO +0.9% (in negotiations with Katie Couric, according to reports), ARWR +0.8% (submits application to begin Phase 2a trial of ARC-520 for the treatment of chronic hepatitis B infection).
(
Читать дальше )